BRAF mutation: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''BRAF mutation''' is a common genetic change in [[cancer]]. | '''BRAF mutation''' is a common genetic change in [[cancer]]. The most common BRAF mutation is the so-called ''[[BRAF V600E mutation]]''. | ||
==General== | ==General== | ||
*BRAF inhibitors (e.g. vemurafenib) | *Clinical implication: BRAF inhibitors (e.g. vemurafenib) are used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal | last1 = Cheng | first1 = L. | last2 = Lopez-Beltran | first2 = A. | last3 = Massari | first3 = F. | last4 = MacLennan | first4 = GT. | last5 = Montironi | first5 = R. | title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. | journal = Mod Pathol | volume = 31 | issue = 1 | pages = 24-38 | month = 01 | year = 2018 | doi = 10.1038/modpathol.2017.104 | PMID = 29148538 }}</ref> | ||
Prevalence by tumour type:<ref name=pmid29148538/> | ===Prevalence=== | ||
BRAF mutations by tumour type:<ref name=pmid29148538/> | |||
*BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors. | *BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors. | ||
*BRAF mutations in ~ 10% of colorectal tumours. | *BRAF mutations in ~ 10% of colorectal tumours. | ||
| Line 10: | Line 11: | ||
*BRAF mutations in ~45-50% of papillary thyroid carcinoma. | *BRAF mutations in ~45-50% of papillary thyroid carcinoma. | ||
*BRAF mutations in ~3% of [[lung adenocarcinoma]]s. | *BRAF mutations in ~3% of [[lung adenocarcinoma]]s. | ||
==See also== | |||
*[[BRAF V600E mutation]]. | |||
*[[KRAS mutation]]. | |||
==References== | ==References== | ||